New data from Denmark shows the HPV vaccine’s powerful long-term impact, while also revealing why cervical cancer screening is still essential.
A Danish study published in the journal Eurosurveillance reports that women who received the human papillomavirus vaccine in their adolescence are significantly less likely to develop human papillomavirus infections later in life.
Background
Prolonged infection with human papillomavirus (HPV) is associated with an increased risk of developing cervical cancer. Early screening and vaccination against HPV are effective strategies to prevent this cancer type.
Screening for precancerous lesions has been a widely considered strategy for secondary prevention of cervical cancer in Europe. Vaccines covering both high-risk and low-risk HPV types have been introduced as a primary preventive intervention at the end of the 2000s.
In Denmark, free public HPV vaccination (4-valent vaccine) was initially offered to all girls aged 13 to 15 in October 2008. It was later introduced to all girls turning 12 in January 2009. In November 2017, a 9-valent vaccine, which covers high-risk HPV types responsible for up to 90% of cervical cancers, was introduced in the country.
Cervical cancer screening is offered to women living in Denmark from the age of 23 years until the age of 64 years. One of the first groups of women who received the 4-valent HPV vaccination as teenage girls in 2008 reached the screening age of 23 years in 2017.
To carefully monitor screening outcomes in these vaccinated women, Trial23, a public health study embedded in the Danish national cervical screening program, was designed to determine the prevalence of HPV infection in cervical cell samples collected during three consecutive rounds of screening invitations.
In the current study, researchers assessed the prevalence of HPV infection in these consecutive cervical samples and the changes in HPV persistence and incidence between the first, second, and third samples.
Key findings
A total of 17,252 women with at least one cervical cell sample were registered in the Trial23 between February 2017 and February 2024. In this study, researchers analyzed 16,955 cervical samples collected from 8,659 women.
The prevalence of any high-risk HPV infection in the first, second, and third rounds of cervical samples was 32%, 28%, and 31%, respectively. The prevalence of HPV types 16 and 18 (high-risk viruses covered by the 4-valent HPV vaccine) remained low over time in all analyzed samples.
The comparison between vaccinated and unvaccinated women revealed significantly lower prevalence of HPV types 16 and 18 in vaccinated women. The prevalence of this virus type was 15 to 17% before vaccination, which reduced to less than 1% in vaccinated women by 2021.
Notably, the study found that about one-third of women still have infections with high-risk HPV that are not covered by the vaccine, and that the incidence of these infections was significantly higher in vaccinated women compared to unvaccinated women. However, the prevalence differences were not statistically significant.
Regarding HPV infection persistence and incidence, the study found a high persistence for both vaccine-covered and non-covered virus types, irrespective of vaccination status. The incidence of HPV types 16 and 18 was significantly lower in vaccinated women compared to that in unvaccinated women. However, the incidence, but not prevalence, of non-covered high-risk HPV types was significantly higher in vaccinated women compared to that in unvaccinated women, a pattern the authors suggest may be due to type replacement or unmasking.
Study significance
The study reports the prevalence of HPV infection in three sets of cervical cell samples collected consecutively from young Danish women who received the 4-valent HPV vaccination in their adolescence.
According to the findings, the prevalence of infection with HPV types 16 and 18 in vaccinated women is currently less than 1%, a significant drop from the pre-vaccination prevalence. In unvaccinated women, the prevalence is 5%, which is also much lower than the pre-vaccination prevalence. The drop in prevalence in unvaccinated women indicates population immunity.
Regarding infections with high-risk HPV types that are not covered by the vaccine, the study reports a prevalence of 30% in vaccinated women and 27% in unvaccinated women, which is a non-significant difference. A persistently high prevalence of non-vaccine high-risk HPV types in both vaccinated and unvaccinated women highlights the need for continuous screening of these generations until women vaccinated as girls with the 9-valent vaccine covering all major HPV types reach the screening age. At this point, the screening model might be reconsidered, with the study suggesting that less intensive but continued screening could be appropriate.
The study finds no significant differences in the persistence of HPV 16 and 18 infections between vaccinated and unvaccinated women, which indicates that the 4-valent vaccine, which covers high-risk HPV types 16 and 18 and low-risk types 6 and 11, is a prophylactic (preventive) vaccine and not a therapeutic vaccine. The conclusion supports the finding that persistence rates were similar regardless of vaccination status.
Overall, the study findings highlight the long-term protective efficacy of the HPV vaccine and advise close monitoring of factors associated with vaccine hesitancy and low vaccine coverage, such as perceived side effects of the vaccine.Journal reference:
News
China makes early progress in using sound waves to stimulate damaged brains
Chinese researchers are testing whether focused ultrasound can help restore consciousness in patients with severe brain injuries, adding to a growing international effort to use sound waves to stimulate deep brain structures without surgery. [...]
Micro-drones fly through the body thanks to ultrasound
At the EPFL, micro-drones have been developed that can be moved without a motor or battery.No motors, no batteries, no electronics on board, just small cavities that convert sound waves into thrust: this is [...]
A Single Enzyme Could Hold the Key to Treating a Devastating Brain Disorder
Blocking an enzyme’s production restored brain growth and healthy behaviors in mice engineered to develop Angelman syndrome, pointing to a possible treatment target. Children with Angelman syndrome begin to show difficulties with thinking and [...]
Scientists Develop a Clever New Way To Kill Cancer Cells From the Inside
Scientists have developed an experimental strategy that exploits a chemical byproduct of cancer cells to produce anticancer drugs directly inside them. Scientists in Japan have developed an experimental method that uses a chemical produced [...]
Our books are available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
After only a short training, people in a coma managed to send targeted signals
Researchers have succeeded in communicating with brain-injured patients who are unconscious. They see enormous potential in this for future treatments. Patients who lie motionless in bed after a severe brain injury and do not [...]
MIT Scientists Reprogram Immune Cells Inside the Body To Destroy Cancer
Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this approach could help people with cancer or autoimmune disease remains unknown. To make a cancer treatment from [...]
Melanoma mRNA Vaccine Shows Promise in Preventing Disease Recurrence
Key takeaways: Phase 3 trial finds personalized intismeran plus pembrolizumab may better prevent high-risk melanoma recurrence after surgery The trial enrolled 1,137 patients and builds on phase 2 results showing about half the recurrence [...]
Scientists Discover a Powerful New Weapon Against a Dangerous Gut Infection
The promise of an experimental treatment for C. difficile gut infections lies partly in the bacteria it leaves alive, according to early laboratory and mouse research. Broad-spectrum antibiotics can disrupt the gut’s microbial community, [...]
Your Bones May Hold a Hidden Clue to Blood Cancer Survival
For people with blood cancers called myelodysplastic syndromes, osteoporosis may hold an overlooked clue to survival, a three-year observational study suggests. In blood cancers that develop in the bone marrow, an important clue to [...]
Researchers Discover What Reading for Pleasure May Be Doing to Your Brain
Reading for pleasure may offer surprising benefits for the brain, with research linking the habit to better mental health, stronger cognitive abilities, and a lower risk of dementia. Reading for pleasure may do far [...]
Scientists Discover a Hidden Trigger That Keeps Inflammation Alive
Inflammation persists after proteins detach from immune receptors, revealing a potential target for autoimmune treatments. Since a Nobel Prize-winning discovery in the 1990s identified molecules called Toll-like Receptors as the guardians of the human [...]
A Virus Gives Itself Away the Moment It Attacks
Researchers have found the trigger behind a powerful bacterial defense against viruses. Viruses that prey on bacteria could become an increasingly important tool for treating bacterial infections, particularly as antibiotic resistance makes some infections [...]
Scientists Discover Aspirin May Slash Dementia Risk by 70% – but Only for Certain People
Aspirin was linked to a sharply lower dementia risk in some older adults, and their genes may hold the clue. A Monash University analysis found that older adults with a particular genetic profile had [...]
Inflammation May Awaken Dormant Cancer Cells Years After Treatment
The body’s response to inflammation may disturb cancer cells that have been lying silent for years, giving them an opportunity to grow again. Researchers at the Francis Crick Institute have found that gut inflammation [...]
Where do nanoparticles go once they enter the body?
New international best practice guidance, co-written at ANSTO, sets out how to measure where nanoparticles like titanium dioxide end up in the body and how long they remain. The guidance has been shared by [...]
